10-Q: International Isotopes Inc. Reports Q1 2025 Results: Revenue Up 12% Driven by Nuclear Medicine Standards

International Isotopes Inc. saw a 12% increase in revenue for Q1 2025, primarily driven by growth in its Nuclear Medicine Standards segment, while experiencing a net loss of $112,694.

Summary

• International Isotopes Inc. (INIS) reported its Q1 2025 financial results, showing a net loss of $112,694 compared to a net loss of $154,051 in Q1 2024.
• The company's revenue increased by 12% to $3,238,900 from $2,904,458 in the same period last year.
• The increase in revenue was primarily driven by a 73% increase in the Nuclear Medicine Standards segment, which saw sales rise to $1,326,766.
• The Theranostics Products segment experienced a 6% decrease in sales, while the Cobalt Products segment saw a 69% decrease.
• The company's operating expenses decreased slightly by 2% to $2,097,053.
• INIS is focusing on its core business segments: Theranostics Products, Cobalt Products, and Nuclear Medicine Standards.
• The company expects to close the sale of its Fluorine Products segment assets within 24 months for $12.5 million.
• INIS believes its current cash balance, along with cash from operations and potential equity or debt financing, will be sufficient to fund operations for the next twelve months.
• As of May 9, 2025, the number of outstanding common shares was 526,385,637 with a par value of $0.01.
• The company's cash and cash equivalents decreased to $1,645,663 at March 31, 2025, from $1,945,523 at December 31, 2024.

Sentiment

Score: 6

Explanation: The report shows mixed results. Revenue is up, and the net loss is reduced, which is positive. However, the company is still operating at a loss, and some segments are experiencing declines. The outlook is cautiously optimistic.

Positives

• Revenue increased by 12% year-over-year, indicating growth in the company's overall business.
• The Nuclear Medicine Standards segment experienced substantial growth, with sales increasing by 73%.
• Net loss decreased from $154,051 to $112,694, showing improved profitability.
• Operating expenses decreased slightly, indicating better cost management.
• The company is focusing on its strongest core business segments.
• The company expects to receive $12.5 million from the sale of its Fluorine Products segment assets.

Negatives

• The company reported a net loss of $112,694 for the quarter.
• The Theranostics Products segment experienced a decrease in sales due to a supplier outage.
• Cobalt Products sales decreased significantly due to timing issues.
• Cash and cash equivalents decreased by $299,860 during the quarter.
• The company is dependent on a few key suppliers and customers.

Risks

• The company has incurred substantial losses since inception.
• Future liquidity and capital funding requirements depend on numerous factors, and there is no assurance that additional capital will be available on acceptable terms.
• The company is dependent on a small number of customers, with approximately 17% of total gross revenue from a single customer.
• The production of Cobalt-60 is dependent on the U.S. Department of Energy.
• Sales of Theranostics Products are dependent on a few key suppliers, and an interruption in production could negatively impact sales.
• A global outage of Gadolinium-153 isotopes resulted in significant lost sales in the Nuclear Medicine Standards segment, and the timeframe to restore supply is uncertain.
• The company's business segments involve the handling or use of radioactive material, requiring an operating license from the NRC and specially trained staff.

Future Outlook

The company expects that cash from operations, equity financing, and its current cash balance will be sufficient to fund operations for the next twelve months and anticipates continued sales growth for its Theranostics Products.

Industry Context

The company operates in the niche market of isotope production and radiopharmaceutical manufacturing, facing competition from both domestic and international players. The growth in the Nuclear Medicine Standards segment reflects the increasing demand for quality control and calibration devices in molecular imaging. The company's focus on its core business segments aligns with the industry trend of specialization and targeted product offerings.

Comparison to Industry Standards

• It's difficult to directly compare INIS's performance to industry standards due to its unique mix of business segments.
• However, companies like Nordion (Canada) and Eckert & Ziegler (Germany) are key players in isotope production and sealed source manufacturing.
• INIS's revenue growth in Nuclear Medicine Standards is a positive sign, as the molecular imaging market is expected to grow.
• The company's net loss, while improved, still lags behind more profitable industry peers.
• The planned sale of the Fluorine Products segment suggests a strategic shift towards core competencies, similar to moves made by other specialized players in the industry.

Stakeholder Impact

• Shareholders: The increased revenue and reduced net loss are positive signs, but the company's continued losses may be a concern.
• Employees: The focus on core business segments may lead to job security in those areas, while the sale of the Fluorine Products segment may impact employees in that division.
• Customers: The company's continued production and distribution of isotopes and radiopharmaceuticals ensures a stable supply for their needs.
• Suppliers: The company's dependence on key suppliers highlights the importance of maintaining strong relationships.
• Creditors: The company's ability to fund operations for the next twelve months provides some assurance, but the continued losses may be a concern.

Next Steps

• Close the sale of the Fluorine Products segment assets within 24 months.
• Continue to focus on core business segments: Theranostics Products, Cobalt Products, and Nuclear Medicine Standards.
• Commercialize additional third-party medical devices and accessories related to the radiopharmaceutical and theranostics spaces.
• Release the Swirler and Tru-Fit Mouthpiece products later in 2025.
• Settle the remaining $199,800 dividend payable to Series C Preferred Stock holders in the second quarter of 2025.

Key Dates

Keywords

International Isotopes, INIS, Nuclear Medicine, Theranostics, Cobalt Products, Fluorine Products, Financial Results, Q1 2025, Radiopharmaceuticals, Isotopes